Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELYSIAN: Aflibercept for High-Risk Proliferative Diabetic Retinopathy
NCT02630277Phase 2Unknown
- Sponsor
- Valley Retina Institute
- Start
- Jan 2016
- Primary completion
- Jan 2017
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of aflibercept in proliferative diabetic retinopathy (PDR), sponsored by Valley Retina Institute. Status: unknown.
02
Drugs
aflibercept
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT02630277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02630277.